SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	ROVAL
OMB Number:	3235-028

Estimated average burden	
hours per response:	0.5

1. Name and Addres Silva Paul M	ss of Reporting Persor	1*	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]	(Check	tionship of Reporting Persor all applicable) Director Officer (give title	n(s) to Issuer 10% Owner Other (specify
INCORPORATE		(Middle) ALS	3. Date of Earliest Transaction (Month/Day/Year) 08/02/2018	Х	below) SVP & Corp Cont	below)
50 NORTHERN AVENUE (Street) BOSTON MA (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing ((Form filed by One Reporti Form filed by More than C Person	ing Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		ction Disposed Of (D) (Instr. 3, 4 and 5) nstr.		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
				v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	08/02/2018		М		1,289	A	\$91.05	17,376	D	
Common Stock	08/02/2018		S ⁽¹⁾		1,289	D	\$174.59	16,087	D	
Common Stock	08/03/2018		М		809	A	\$86.52	16,896	D	
Common Stock	08/03/2018		S ⁽¹⁾		809	D	\$174.2	16,087	D	
Common Stock								169	Ι	401(K)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) o Disp of (I	oosed D) tr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		te Amount of		nt of Derivative ities Security lying (Instr. 5) ttive Security		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$91.05	08/02/2018		М			1,289	(2)	02/01/2026	Common Stock	1,289	\$0.00	7,735	D	
Stock Option (Right to Buy)	\$86.52	08/03/2018		М			809	(3)	02/02/2027	Common Stock	809	\$0.00	8,090	D	

Explanation of Responses:

1. Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1.

2. The option vests in 16 quarterly installments from 2/2/2016.

3. The option vests in 16 quarterly installments from 2/3/2017.

Remarks:

/s/ Stephen Migausky,

Attorney-in-Fact

08/06/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.